Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

Trial Details

NCT ID
NCT04545762
Phase
PHASE1
Sponsor
C. Babis Andreadis
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Fludarabine
  • Cyclophosphamide
  • anti-CD19 CAR-T cells
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Dose expansion Cohorts:
  • Cohort B (Burkitt):
  • Participants must have a diagnosis of relapsed or refractory Burkitt Lymphoma
  • Participants with Burkitt lymphoma must have relapsed or failed to respond to at least 1 prior line of multiagent chemoimmunotherapy with prior exp…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →